Cite
HARVARD Citation
Holch, J. et al. (2019). Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). European journal of cancer. pp. 115-125. [Online].